The latest data point for PFE's P/B Ratio in Q1'26 stands at 1.75, reflecting a modest decline of 1.6% from the previous quarter's value of 1.78 in Q4'25, indicating a slight compression in the stock's valuation relative to its book value. Over the period from Q2'23 to Q1'26, the P/B Ratio has exhibited a predominantly downward trend, starting at 2.04 and reaching a low of 1.50 in Q1'25 before a partial rebound to 1.75, with an overall decline of approximately 14% that suggests increasing market skepticism toward the company's asset valuation amid volatility in the pharmaceutical sector. Notable fluctuations include a temporary uptick to 1.92 in Q2'24, followed by consistent softening through Q3'25, highlighting periods of relative stability interspersed with downward pressure.